Susana Hernandez, MSc

Susana Hernandez, MSc, serves as Director of Cell Therapy at Immunocine and has been a foundational force behind the organization’s scientific rigor, translational integrity, and laboratory excellence since its inception.

Susana earned her undergraduate degree in Pharmaceutical Sciences and her Master’s degree in Clinical Biomedicine from the University of the Americas Puebla (UDLAP), followed by a second Master’s degree in Bioethics from Anáhuac University in Cancún. This rare combination of advanced scientific training and ethical expertise uniquely positions her to guide Immunocine’s cell therapy programs with both precision and responsibility.

With over a decade of experience as an academic educator, Susana has taught Molecular Biology, Genomics, and Cell Physiology at Anáhuac University (Cancún) and the University of Quintana Roo. Her teaching background reinforces her ability to translate complex biological concepts into reproducible, high-integrity laboratory processes—an essential skill in advanced cell therapy development.

In 2018, Susana participated in genome-editing research at the University of Freiburg, where she conducted experiments supporting the development of targeted therapies for hematological malignancies. She has also completed specialized certifications in Medical Genetics through the University of Valencia and in the Administration of Clinical Studies in Latin America through the University of California, San Diego.

At Immunocine, Susana played a critical role in ensuring the faithful and scientifically precise transfer of dendritic cell vaccine protocols into the Immunocine laboratory environment. Her deep expertise in molecular biology, dendritic cell functionality, and immune system analysis ensures that every patient-specific vaccine is manufactured with uncompromising accuracy, consistency, and quality.

Beyond execution, Susana leads ongoing laboratory research and innovation efforts aimed at continuously improving cell processing, immune profiling, and therapeutic outcomes. Her work bridges bench science and clinical impact, embodying Immunocine’s commitment to evolving cancer care through evidence-based innovation.

Susana’s leadership reflects the spirit of Immunocine: science without shortcuts, ethics without compromise, and an unwavering dedication to advancing personalized immunotherapy for patients who deserve both hope and excellence.